-
Mashup Score: 21
Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA ® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla ® ) met its primary endpoint of progression-free survival (PFS). Patients in the trial had unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer and had received previous treatment with a taxane and trastuzumab. Overall survival (OS) data, a secondary endpoint, are not yet mature. Discontinuations due to adverse events were more common in the combination arm of the trial, but no new safety signals emerged for the combination. “We are encouraged by these results for TUKYSA in combination with Kadcyla ® in metastatic HER2-positive breast cancer, including in patients with brain metastases,” said Roger Dansey, President of Research and Development and Chief Medical Officer at Seagen. “We plan to present the HER2CLIMB-02 data
Source: investor.seagen.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 7
Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA ® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla ® ) met its primary endpoint of progression-free survival (PFS). Patients in the trial had unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer and had received previous treatment with a taxane and trastuzumab. Overall survival (OS) data, a secondary endpoint, are not yet mature. Discontinuations due to adverse events were more common in the combination arm of the trial, but no new safety signals emerged for the combination. “We are encouraged by these results for TUKYSA in combination with Kadcyla ® in metastatic HER2-positive breast cancer, including in patients with brain metastases,” said Roger Dansey, President of Research and Development and Chief Medical Officer at Seagen. “We plan to present the HER2CLIMB-02 data
Source: investor.seagen.comCategories: Hem/Oncs, Latest HeadlinesTweet-
T-DM1 plus tucatinib is a positive trial. Look forward to data and brain Mets population! Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival #bcsm https://t.co/GKvUiS2Rro
-
-
Mashup Score: 0
– First treatment option combining an antibody-drug conjugate plus a PD-1 inhibitor in this patient population – Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced the U.S. Food and Drug Administration (FDA) has granted PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) accelerated approval in the U.S. as a combination therapy for the treatment of adult…
Source: investor.seagen.comCategories: Hem/Oncs, Latest HeadlinesTweet-
EV/ pembro aporoved in cis ineligible patients. Great news for out pts. How do we select carbo/ gem vs EV/ pembro ? https://t.co/l3UesKk28t
-
-
Mashup Score: 3ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma - 3 year(s) ago
– Full Data from Phase 3 ECHELON-1 Clinical Trial to be Submitted for Presentation at Upcoming Medical Meeting – Seagen Inc. (Nasdaq:SGEN) today announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival (OS) (p=0.009) in patients with advanced classical Hodgkin lymphoma (cHL) following treatment with ADCETRIS (brentuximab vedotin)…
Source: investor.seagen.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@graham74GC @CMoskowitzMD btw, ECHELON -1 now shows OS benefit with HR 0.59 ( press release) Is it in ASCO abstracts? https://t.co/WqFH0pEeGP
-
-
Mashup Score: 0ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma - 3 year(s) ago
– Full Data from Phase 3 ECHELON-1 Clinical Trial to be Submitted for Presentation at Upcoming Medical Meeting – Seagen Inc. (Nasdaq:SGEN) today announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival (OS) (p=0.009) in patients with advanced classical Hodgkin lymphoma (cHL) following treatment with ADCETRIS (brentuximab vedotin)…
Source: investor.seagen.comCategories: Hem/Oncs, Latest HeadlinesTweet-
ECHELON-1 overall survival advantage What does it mean? Seagen announce 41% reduction in OS with AAVD in stage III/IV pts compared with ABVD with median 6y FU. Some thoughts (follow the thread) 🧵 #lymsm #Hodgkin https://t.co/w7g1tiD1h9
-
-
Mashup Score: 3
– Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial – – First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have Previously Received One or More Prior Therapies, Based on Cohort 2 of Pivotal EV-201 Trial – Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,…
Source: investor.seagen.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to see EV approved for cis-ineligible patients after first line PD-1/L1. https://t.co/3HmgpI5Gty
-
Industry Release‼️ Seagen reports success in HER2CLIMB-02🧗 trial of tucatinib and ado-trastuzumab emtansine combo for HER2positive🧬metastatic #BreastCancer ✅Improved PFS ✅OS data pending @OncoAlert🚨 https://t.co/Qglt07u201 https://t.co/0KTO1M76Js